ClinicalTrials.gg
CompletedNCT00029861Updated Apr 20, 2009

Obese Patients With or Without Comorbidities (RIO-North America)

A Phase 3 interventional study of Rimonabant (SR141716) in Obesity and Weight Loss, sponsored by Sanofi. Completed at 51 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-20.

Sponsored by Sanofi · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,045
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
2nd of 21
3,045 · median 643
Started
2001
with 3 others
Phase 3
18 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 2nd largest by enrollment, is one of 4 that started in 2001, is one of 18 in phase 3, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities

03

Conditions studied

  • Obesity
  • Weight Loss

Keywords

  • Weight Loss
  • Obesity
  • Weight Reduction
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)
  • (Body Mass Index) of 30 or greater in patients with or without comorbidities, or BMI greater than 27 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
3,045 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in body weight

Secondary outcomes

  1. Metabolic parameters

07

Study locations

51 sites
  • Radiant Research
    Birmingham, Alabama 35209, United States
  • Radiant Research
    Phoenix, Arizona 85013, United States
  • East Bay Clinical Trial Center
    Concord, California 94520, United States
  • Feighner Research Institute
    San Diego, California 92121, United States
  • Scripps Clinic
    San Diego, California 92130, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Ranch View Family Medicine
    Highlands Ranch, Colorado 80130, United States
  • Longmont Medical Research Network
    Longmont, Colorado 80501, United States
  • Health Core, Inc.
    Newark, Delaware 19713, United States
  • George Washington Univ. Wieght Mmgt Program
    Washington, District of Columbia 20037, United States
  • Miami Research Associates
    Miami, Florida 33173, United States
  • Anchor Research Center
    Naples, Florida 34102, United States
  • Central Florida Clinical Solutions
    Ocoee, Florida 34761, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32806, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Medical Dietetics, Inc.
    Atlanta, Georgia 30339, United States
  • Springfield Diabetes and Endocrine Center
    Springfield, Illinois 62704, United States
  • Medical Research Consortium
    Indianapolis, Indiana 46208, United States
  • Wichita Clinic, PA
    Wichita, Kansas 67208, United States
  • University of KY Internal Medicine
    Lexington, Kentucky 40536-9841, United States
  • Pennington Center
    Baton Rouge, Louisiana 70808, United States
  • JM Clinical Trials, Inc.
    Swansea, Massachusetts 02777, United States
  • Montana Medical Research, LLC
    Missoula, Montana 59804, United States
  • Endocrinology and Diabetes Consultants, PC
    Dover, New Hampshire 03820, United States
  • Radiant Research
    Lawrenceville, New Jersey 08648, United States
  • Lovelace Scientific Resources
    Albuquerque, New Mexico 87108, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Comprehensive Weight Control Program
    New York, New York 10021, United States
  • St. Luke's Roosevelt Hospital Center
    New York, New York 10025, United States
  • Center for Nutrition and Preventive Medicine
    Charlotte, North Carolina 28207, United States
  • Multi-Specialty Research Associates of North Carolina
    Raleigh, North Carolina 27609, United States
  • South Dayton Research Associates
    Beavercreek, Ohio 45431, United States
  • Lindner Clinical Trials Center
    Cincinnati, Ohio 45219, United States
  • Radiant Research
    Columbus, Ohio 43212, United States
  • Radiant Research
    Portland, Oregon 97201, United States
  • SFM Clinical Trials
    Scotland, Pennsylvania 17254, United States
  • Radiant Research
    Wyomissing, Pennsylvania 19610, United States
  • ClinSearch
    Chattanooga, Tennessee 37404, United States
  • Clinical Research Associates, Inc
    Nashville, Tennessee 37203, United States
  • Radiant Research
    Austin, Texas 78758, United States
  • Dallas Diabetes and Endocrine Center
    Dallas, Texas 75230, United States
  • nTouch Research
    Houston, Texas 77024, United States
  • Quality Research, Inc.
    San Antonio, Texas 78209, United States
  • Advanced Clinical Research
    Salt Lake City, Utah 84102, United States
  • Commonwealth Clinical Research Specialists (CCRS)
    Richmond, Virginia 23226, United States
  • Rainer Clinical Research Center, Inc.
    Renton, Washington 98055-5704, United States
  • Clinical Nutrition Clinic, University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Corunna Medical Clinic
    Corunna, Ontario N0N1G0, Canada
  • Quarry Family Medicine Clinic
    Kingston, Ontario K7L3E4, Canada
  • Trial Management Group
    Richmond Hill, Ontario L4E3S8, Canada
  • Group North
    Windsor, Ontario N8X3V6, Canada
08

References and documents

Publications

  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761. Erratum In: JAMA. 2006 Mar 15;295(11):1252. PubMed 16478899 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2002
First posted
Jan 24, 2002
Start
Aug 2001
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Last update
Apr 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00029861
Lead sponsor
Sanofi
First posted
Jan 24, 2002
Start date
Aug 2001
Primary completion
Apr 2004
Completion
Apr 2004
Last update
Apr 20, 2009

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion